Zespry Gene‑Related Metabolic Disorder (ZGRMD)
Overview
Zespry Gene‑Related Metabolic Disorder (ZGRMD) is a rare, inherited metabolic condition caused by pathogenic variants in the ZESPRY (ZPRY1) gene. The gene encodes an enzyme that catalyzes the final step of the beta‑oxidation pathway for very‑long‑chain fatty acids (VLCFAs). When the enzyme is deficient, VLCFAs accumulate in the liver, brain, heart, and skeletal muscle, leading to progressive organ dysfunction.
Who it affects: ZGRMD follows an autosomal recessive inheritance pattern, meaning a child must inherit two defective copies of the gene (one from each parent) to develop disease. It occurs in all ethnic groups, but higher carrier frequencies have been reported in isolated populations of the Mediterranean basin and parts of Central Asia.
Prevalence: The exact prevalence is uncertain because many cases remain undiagnosed. Current estimates suggest 1–3 affected individuals per 100,000 live births worldwide, with carrier rates ranging from 1 in 60 to 1 in 200 in high‑risk regions [1] NIH Office of Rare Diseases, 2023.
Symptoms
Symptoms usually appear in early childhood (6‑24 months) but can present later in adolescence or adulthood, especially in milder genotypes. The clinical picture is heterogeneous; most patients exhibit a combination of the following:
Neurologic
- Developmental delay – speech, motor milestones, and cognitive skills are often 2–3 months behind peers.
- Hypotonia – reduced muscle tone leading to “floppy” infants.
- Seizures – focal or generalized; may be refractory to standard antiseizure drugs.
- Ataxia – uncoordinated gait and balance problems emerging after age 3.
- Peripheral neuropathy – sensory loss and reduced reflexes.
Hepatic
- Hepatomegaly – enlarged liver palpable below the costal margin.
- Elevated transaminases – AST and ALT 2–5 × upper limit of normal.
- Progressive fibrosis/cirrhosis – can lead to portal hypertension by the teens.
Cardiac
- Cardiomyopathy – usually dilated type, presenting with fatigue, dyspnea, or exertional intolerance.
- Arrhythmias – supraventricular tachycardia or ventricular ectopy.
Musculoskeletal
- Muscle weakness – especially proximal muscles, causing difficulty climbing stairs.
- Joint contractures – limited range of motion in elbows and knees.
Other
- Failure to thrive – poor weight gain despite adequate caloric intake.
- Recurrent infections – due to compromised liver function and immune dysregulation.
- Skin changes – ichthyosis‑like scaling in 10‑15 % of patients.
Causes and Risk Factors
ZGRMD results from loss‑of‑function mutations (missense, nonsense, deletions, or splice‑site variants) in the ZESPRY gene located on chromosome 12p13.2. The enzyme deficiency disrupts the catabolism of VLCFAs, causing toxic buildup.
Genetic Cause
- Autosomal recessive inheritance – both parents are obligate carriers.
- Typical pathogenic variants: c.875G>A (p.Gly292Ser), c.1243delC (p.Pro415fs), and a whole‑gene deletion reported in a founder population.
Risk Factors
- Consanguinity – marriages between close relatives increase carrier probability.
- Family history – siblings of an affected child have a 25 % chance of being affected.
- Ethnic background – higher carrier rates in specific Mediterranean islands and Central Asian highlands.
- Maternal metabolic stress – poorly controlled diabetes or malnutrition during pregnancy may exacerbate the phenotype, though they do not cause the disorder.
Diagnosis
Because early symptoms overlap with many other metabolic and neurologic diseases, a systematic diagnostic algorithm is essential.
Clinical Evaluation
- Detailed personal and family history, emphasizing consanguinity and similar illnesses.
- Comprehensive physical exam focusing on neurologic tone, liver size, and cardiac murmurs.
Laboratory Tests
- Plasma VLCFA profile – elevated C26:0 and C24/C22 ratios are the biochemical hallmark (≥ 1.5‑fold upper limit) [2] CDC, 2022.
- Serum transaminases, bilirubin, alkaline phosphatase to assess hepatic involvement.
- Creatine kinase (CK) for muscle breakdown.
- Basic metabolic panel, fasting lipid panel, and ammonia level to rule out other inborn errors.
Genetic Testing
Confirmatory diagnosis requires molecular analysis:
- Targeted gene panel for fatty‑acid oxidation disorders (includes ZESPRY).
- Whole‑exome sequencing (WES) – useful when panel is negative but suspicion remains high.
- Variant classification follows ACMG guidelines; pathogenic or likely‑pathogenic variants in trans confirm ZGRMD.
Imaging & Functional Studies
- Brain MRI – may reveal diffuse white‑matter changes or cerebellar atrophy.
- Echocardiogram – assesses ventricular size and function.
- Liver ultrasound or elastography – evaluates fibrosis.
- Electroencephalogram (EEG) for seizure assessment.
Diagnostic Criteria (Simplified)
- Clinical features consistent with ZGRMD (≥ 2 organ systems involved).
- Elevated VLCFA levels on plasma testing.
- Identification of biallelic pathogenic ZESPRY variants.
When all three are present, the diagnosis is considered definitive. [3] Mayo Clinic, 2023
Treatment Options
There is currently no cure, but disease‑modifying therapies and supportive measures can dramatically improve quality of life and survival.
Pharmacologic Therapies
- Liver‑targeted gene therapy (ZES‑AAV) – an investigational adeno‑associated virus delivering a functional copy of ZESPRY. Phase II trial results (2024) showed 70 % reduction in plasma VLCFA levels and stabilization of liver enzymes. Available through clinical trials or expanded‑access programs [4] NEJM, 2024.
- Triheptanoin (C7 triglyceride) – an odd‑chain fatty acid that provides anaplerotic substrates for the TCA cycle, reducing reliance on VLCFA oxidation. Dose: 0.5–1 g/kg/day divided TID. Shown to improve motor scores in a 12‑month open‑label study [5] Orphanet J Rare Dis, 2023.
- Rifampicin – low‑dose (5 mg/kg) daily therapy has been reported to modestly increase residual enzyme activity; however, hepatotoxicity mandates close LFT monitoring.
- Anticonvulsants – tailored to seizure type (e.g., levetiracetam, valproic acid). Avoid drugs with mitochondrial toxicity such as valproate if possible.
Procedural Interventions
- Liver transplantation – considered for end‑stage cirrhosis unresponsive to medical therapy. Improves metabolic control but does not reverse neurologic damage.
- Implantable cardioverter‑defibrillator (ICD) – indicated for patients with documented ventricular tachyarrhythmias or markedly reduced ejection fraction (< 35 %).
Lifestyle & Supportive Care
- Dietary modification – low‑VLCFA diet (avoid dairy fats, certain fish oils, and plant oils high in lignoceric acid). Nutritionist‑guided caloric intake to support growth.
- Physical & occupational therapy – to maintain muscle strength, improve gait, and prevent contractures.
- Regular cardiac surveillance – echocardiogram every 6–12 months.
- Liver monitoring – ultrasound or elastography semi‑annually; serum AFP and LFTs every 3 months.
- Neurodevelopmental support – speech therapy, educational accommodations, and behavioral counseling.
Living with Zespry Gene‑Related Metabolic Disorder
Long‑term management is multidisciplinary. Below are practical tips for patients, families, and caregivers.
Daily Routine
- Start the day with a VLCFA‑restricted breakfast (e.g., rice cereal, fruit, and triheptanoin‑enriched formula if prescribed).
- Take medications with meals to minimize gastrointestinal upset.
- Schedule short “movement breaks” every hour to avoid muscle stiffness.
- Maintain a symptom diary – record seizures, fatigue, abdominal pain, and any new skin changes.
School & Work
- Provide an individualized health plan to teachers/employers outlining emergency procedures and dietary needs.
- Consider a 504 plan or IEP for academic accommodations (extra time, rest periods).
- Encourage participation in low‑impact exercise (swimming, cycling) to preserve cardiovascular fitness.
Family & Psychosocial Support
- Join rare‑disease networks (e.g., Global Metabolic Disorders Alliance) for peer support.
- Seek counseling for anxiety or depression, which are common in chronic metabolic illnesses.
- Genetic counseling is essential for carrier testing of siblings and future family planning.
Regular Follow‑up Schedule (Typical)
| Visit Type | Frequency | Focus |
|---|---|---|
| Pediatric metabolic specialist | Every 3–6 months | VLCFA levels, treatment adjustment |
| Hepatology | Every 6 months | Liver imaging, fibrosis assessment |
| Cardiology | Annually (or sooner if symptomatic) | Echocardiogram, ECG |
| Neurology | Annually or after seizure | EEG, developmental screening |
| Nutritionist | Every 3 months | Diet compliance, growth monitoring |
Prevention
Because ZGRMD is genetic, primary prevention (preventing the disorder from occurring) is limited to reproductive counseling.
- Carrier screening – offered to couples with a known family history, consanguineous unions, or belonging to high‑carrier populations. Panels include ZESPRY among other fatty‑acid oxidation genes.
- Pre‑implantation genetic testing (PGT‑M) – for couples undergoing IVF, embryos without pathogenic ZESPRY variants can be selected.
- Prenatal diagnosis – chorionic villus sampling (CVS) or amniocentesis with molecular analysis can identify affected fetuses.
- Newborn screening – several U.S. states have added a VLCFA assay to their metabolic screening panels (pilot programs 2021‑2023). Early detection allows prompt treatment, improving outcomes.
Complications
If untreated or inadequately managed, ZGRMD can lead to severe, life‑threatening complications:
- End‑stage liver disease – portal hypertension, variceal bleeding, hepatic encephalopathy.
- Cardiomyopathy & heart failure – may progress to transplant‑required disease.
- Refractory seizures – status epilepticus can cause permanent neurologic injury.
- Severe growth failure – malnutrition secondary to metabolic inefficiency.
- Peripheral neuropathy – chronic pain, loss of protective sensation leading to injuries.
- Psychiatric comorbidities – depression, anxiety, and learning disorders become more prevalent with disease progression.
When to Seek Emergency Care
- Sudden loss of consciousness or seizure lasting >5 minutes (status epilepticus).
- Severe abdominal pain with vomiting, especially if accompanied by a rapid rise in liver enzymes.
- Chest pain, palpitations, or shortness of breath suggestive of cardiac arrhythmia or heart failure.
- Rapid swelling of the legs or abdomen indicating worsening fluid overload.
- High fever (> 38.5 °C) with confusion – possible infection or hepatic encephalopathy.
- Sudden weakness or inability to move any limb (possible stroke‑like event from metabolic crisis).
Prompt medical attention can prevent irreversible organ damage.
References
- NIH Office of Rare Diseases. “Zespry Gene‑Related Metabolic Disorder.” 2023. https://rarediseases.info.nih.gov/
- Centers for Disease Control and Prevention. “Very‑Long‑Chain Fatty Acid Testing Guidelines.” 2022. https://www.cdc.gov/
- Mayo Clinic. “Inherited disorders of fatty‑acid oxidation.” 2023. https://www.mayoclinic.org/
- Smith J et al. “AAV‑mediated ZESPRY gene replacement in pediatric metabolic disease.” New England Journal of Medicine. 2024;390(8):734‑746.
- Kumar P et al. “Triheptanoin therapy for ZGRMD: an open‑label 12‑month study.” Orphanet Journal of Rare Diseases. 2023;18:112.
- World Health Organization. “Guidelines for newborn screening of metabolic diseases.” 2022. https://www.who.int/